WellDoc BlueStar

By Jonah Comstock January 11, 2018
Correction: A previous version of this story mistated the projected timeline for the combined product. It is Q1 this year, not Q1 next year. WellDoc and Voluntis, two companies with FDA-cleared, clinically validated platforms aimed at the management of Type 2 diabetes, have signed a commercial agreement to combine their technologies and offer joint products in the future. “My thought is that a...
By Dave Muoio January 4, 2018
An analysis contracted by WellDoc found that the company’s digital therapeutic for Type 2 diabetes management could lead to an average savings of more than $250 per patient per month. “The cost of a well-controlled diabetes patient will typically range in the $13,000 range [to] $20,000 annually. When you contrast that with the cost of a patient that doesn’t have diabetes, that number is typically...
By Jonah Comstock January 4, 2017
WellDoc announced today a partnership with the American Association of Diabetes Educators (AADE), a professional membership organization of over 14,000 diabetes educators. WellDoc will incorporate educational content from AADE into its FDA-cleared, reimburseable BlueStar system for diabetes management.  "We were able to build a curriculum that will be able to be delivered in a contextually guided...
By Jonah Comstock June 13, 2016
A number of pieces of interesting health tech news came out of the 76th Annual Scientific Sessions of the American Diabetes Association, held this weekend in New Orleans. Here’s a roundup of the highlights. Updated 6/15/2016 to include some more news items. IBM’s Medtronic partnership gets a name. Information has been trickling out about Medtronic’s collaboration with IBM Watson Health that was...
By Jonah Comstock April 20, 2015
Two of the biggest medical journals in the world have taken up some big picture mobile health questions this week: How are patients to know which medical apps work out of the sea of available options, and should healthy patients be making use of mobile health apps and devices at all? The first question is the subject of a recent article in the Journal of the American Medical Association, while...
By Brian Dolan January 10, 2014
Baltimore, Maryland-based WellDoc, one of the earliest and best known mobile health companies focused on diabetes management, has landed a $20 million round of investment that includes contributions from Merck Global Health Innovation Fund and Windham Venture Partners. The announcement marks WellDoc's first round of institutional money -- the company has long relied on angel investors and debt...
By Jonah Comstock October 30, 2013
WellDoc's BlueStar system. Baltimore, Maryland-based mobile health company WellDoc has developed a model that can predict hypoglycemic events in patients with Type 2 diabetes 91 percent of the time based on once-a-day patient blood glucose testing. Predicting hypoglycemic events, a term for when people with diabetes are dangerously low blood sugar, up to 24 hours before they occur -- as...
By Jonah Comstock July 1, 2013
A mobile app released last year by Pfizer. A staggering 90 percent of chronic patients in the US would accept a mobile app prescription from their physician, as opposed to only 66 percent willing to accept a prescription of medication, according to a recent survey from health communications firm Digitas Health. Digitas presented preliminary research findings at a recent event in London, PMLiVE...

Editor's Pick